Press Releases

 

 
Press Releases
Date Title and Summary View
Dec 19, 2017 RANCHO CUCAMONGA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") for Sodium Nitroprusside Injection 25mg/mL, 2mL single dose vial, indicated for the immediate reductio...
Nov 29, 2017 RANCHO CUCAMONGA, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of two abbreviated new drug applications (ANDAs) for Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg/mL, 1mL vial, and 1mL prefilled syri...
Nov 20, 2017 RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 10:30 a.m. Eastern Time in New York, NY....
Nov 8, 2017 RANCHO CUCAMONGA, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2017. Third Quarter Highlights Net revenues of $57.9 million for the third quart...
Oct 31, 2017 RANCHO CUCAMONGA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2017, ended September 30, 2017, after the market closes on Wednesday, November 8, 2017, and will hold a conference call to discuss its financial result...
Sep 25, 2017 RANCHO CUCAMONGA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application (ANDA) for Neostigmine Methylsulfate Injection, USP, 1mg/mL, 10mL, and 0.5mg/mL, 10mL vial. Amphastar...
Sep 20, 2017 RANCHO CUCAMONGA, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on September 19, 2017, the U.S. Food and Drug Administration ("FDA") granted approval of the company's abbreviated new drug application ("ANDA") for Sodium Bicarbonate injection 8.4% in the 50 mL Luer-Jet®...
Aug 30, 2017 RANCHO CUCAMONGA, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2017 Wells Fargo Securities Healthcare Conference on Wednesday, September 6, 2017 at 1:50 p.m. Eastern Time in Boston, MA. T...
Aug 9, 2017 RANCHO CUCAMONGA, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2017. Second Quarter Highlights Net revenues of $65.2 million for the secon...
Aug 2, 2017 RANCHO CUCAMONGA, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2017, ended June 30, 2017, after the market closes on Wednesday, August 9, 2017, and will hold a conference call to discuss its financial results at 2...
Page:
1
... NextLast
= add release to Briefcase

 

Copyright © 2018 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States